Johnson & Johnson Pre-Tax Income increased by 20.6% to $5.99B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 56.1%, from $13.63B to $5.99B. Over 4 years (FY 2021 to FY 2025), Pre-Tax Income shows an upward trend with a 9.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
This provides a view of profitability that is not skewed by varying tax rates or one-time tax credits.
A company's profits before the deduction of corporate income tax. It combines operating performance with non-operating f...
Used to compare companies across different tax jurisdictions to see who generates more raw profit.
income_before_tax| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.66B | $3.85B | $4.84B | $5.86B | $5.84B | $5.82B | $3.84B | -$1.29B | $6.31B | $5.22B | $4.83B | $3.71B | $5.75B | $3.34B | $3.89B | $13.63B | $6.49B | $7.49B | $4.97B | $5.99B |
| QoQ Change | — | -42.2% | +25.6% | +21.2% | -0.4% | -0.3% | -34.0% | -133.5% | +590.0% | -17.3% | -7.5% | -23.0% | +54.8% | -41.9% | +16.4% | +250.7% | -52.4% | +15.4% | -33.7% | +20.6% |
| YoY Change | — | — | — | — | -12.3% | +51.3% | -20.6% | -122.0% | +8.0% | -10.4% | +25.7% | +388.6% | -8.8% | -36.0% | -19.5% | +267.0% | +12.9% | +124.5% | +27.8% | -56.1% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $5.46B | $4.48B | $4.01B | $5.21B | $5.55B | $6.45B | $5.06B | $5.32B |
| Medical Devices | $1.09B | $1.06B | $72.00M | $1.42B | $1.20B | $1.29B | $201.00M | $1.24B |
| Total | $5.75B | $3.34B | $3.89B | $13.63B | $6.49B | $7.49B | $4.97B | $5.99B |